JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease

MT Newswires Live

Jan 06, 2025

JCR Pharmaceuticals (TYO:4552) and Modalis Therapeutics (TYO:4883) have validated the initial proof of concept for a novel gene therapy targeting a central nervous system (CNS) disease, according to a filing on Monday.

Building on this success, they have signed a new joint research agreement to conduct pre-clinical studies, read the filing.

The research will utilize JCR's J-Brain Cargo technology to cross the blood-brain barrier and Modalis' CRISPR-GNDM technology for gene modulation.

The goal is to develop an innovative gene therapy offering improved efficacy and safety through minimally invasive intravenous injection.

Modalis Therapeutics' shares gained nearly 7% at market close.

Price (JPY): $109.00, Change: $+7.0, Percent Change: +6.86%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501400273"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501400273\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501400273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-06 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501400273","market":"fut","top_or_hot":-1,"title":"JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease","media":"MT Newswires Live","content":"<html><body><p> JCR Pharmaceuticals (TYO:4552) and Modalis <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TYO:4883) have validated the initial proof of concept for a novel gene therapy targeting a central nervous system (CNS) disease, according to a filing on Monday.</p><p>Building on this success, they have signed a new joint research agreement to conduct pre-clinical studies, read the filing.</p><p>The research will utilize JCR's J-Brain Cargo technology to cross the blood-brain barrier and Modalis' CRISPR-GNDM technology for gene modulation.</p><p>The goal is to develop an innovative gene therapy offering improved efficacy and safety through minimally invasive intravenous injection.</p><p>Modalis Therapeutics' shares gained nearly 7% at market close.</p><p>Price (JPY): $109.00, Change: $+7.0, Percent Change: +6.86%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-06 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> JCR Pharmaceuticals (TYO:4552) and Modalis <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TYO:4883) have validated the initial proof of concept for a novel gene therapy targeting a central nervous system (CNS) disease, according to a filing on Monday.</p><p>Building on this success, they have signed a new joint research agreement to conduct pre-clinical studies, read the filing.</p><p>The research will utilize JCR's J-Brain Cargo technology to cross the blood-brain barrier and Modalis' CRISPR-GNDM technology for gene modulation.</p><p>The goal is to develop an innovative gene therapy offering improved efficacy and safety through minimally invasive intravenous injection.</p><p>Modalis Therapeutics' shares gained nearly 7% at market close.</p><p>Price (JPY): $109.00, Change: $+7.0, Percent Change: +6.86%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNS","symbol_name":"科恩-斯蒂尔斯金融","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501400273","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501400273","pubTimestamp":1736154238,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"JCR Pharmaceuticals  and Modalis Therapeutics  have validated the initial proof of concept for a novel gene therapy targeting a central nervous system  disease, according to a filing on Monday.Building on this success, they have signed a new joint research agreement to conduct pre-clinical studies, read the filing.The research will utilize JCR's J-Brain Cargo technology to cross the blood-brain barrier and Modalis' CRISPR-GNDM technology for gene modulation.The goal is to develop an innovative gene therapy offering improved efficacy and safety through minimally invasive intravenous injection.Modalis Therapeutics' shares gained nearly 7% at market close.Price : $109.00, Change: $+7.0, Percent Change: +6.86%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNS":"科恩-斯蒂尔斯金融","BK4139":"生物科技","BK4135":"资产管理与托管银行","LENZ":"Therapeutics"},"translate_title":"JCR Pharmaceuticals和Modalis Therapeutics推进中枢神经系统疾病基因治疗研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CNS":1},"content_text":"JCR Pharmaceuticals (TYO:4552) and Modalis Therapeutics (TYO:4883) have validated the initial proof of concept for a novel gene therapy targeting a central nervous system (CNS) disease, according to a filing on Monday.Building on this success, they have signed a new joint research agreement to conduct pre-clinical studies, read the filing.The research will utilize JCR's J-Brain Cargo technology to cross the blood-brain barrier and Modalis' CRISPR-GNDM technology for gene modulation.The goal is to develop an innovative gene therapy offering improved efficacy and safety through minimally invasive intravenous injection.Modalis Therapeutics' shares gained nearly 7% at market close.Price (JPY): $109.00, Change: $+7.0, Percent Change: +6.86%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}